5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Imaging the Force of Cancer (FORCE)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Voir le projet
18
Participants partenaires
TERMINÉ
Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex (EPISTOP)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,
Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of epilepsy is highest in infancy and 50% of children experience epilepsy-related comorbidities, such as developmental delay and autism. The development of epilepsy (epileptogenesis), extensively studied in animals, is barely studied in humans, as patients usual ...
Voir le projet
16
Participants partenaires
TERMINÉ
Local Immunomodulation around implants by innovative auxiliary hydrogel-based systems encapsulating autologous and phenotype controlled macrophages (IMMODGEL)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
IMMODGEL aims to identify adverse immune reactions to dental and larynx titanium implants and to develop a novel therapeutic strategy to significantly decrease the implant and medical device failure caused by these reactions via design of an innovative immunomodulatory system. The system will be designed to be fixed to an implant via an adhesive polyelectrolyte multilayer and control the immune re ...
Voir le projet
9
Participants partenaires
TERMINÉ
Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,
"In 2010 a widely marketed drug for the treatment of type 2 diabetes (T2DM) (rosiglitazone) was taken from the market as it was associated with an increased risk of myocardial infarction, a T2DM complication it was actually supposed to prevent. This example shows several things. First, the approval requirements do not guarantee a longer term positive benefit risk profile. Second, large scale postm ...
Voir le projet
19
Participants partenaires
TERMINÉ
Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES)
Date du début: 1 févr. 2010, Date de fin: 31 janv. 2015,
CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these different studies would lead to an integrated appr ...
Voir le projet